Jim Cramer, the long‑time host of “Mad Money,” has rarely expressed enthusiasm for a biotech company, yet he has now declared that he “likes having a position in Moderna.” The statement comes at a time when the company’s mRNA technology has moved beyond COVID‑19 vaccines into a broader range of therapeutic applications, and it reflects a growing belief that Moderna’s pipeline could generate significant upside in the coming years.
In the crypto world, sentiment is currently at the bottom of the fear‑greed cycle, with the index sitting at an extreme‑fear level. Bitcoin and Ethereum are hovering around $62,660 and $1,770 respectively, each showing modest gains of less than 1 % over the past 24 hours. This low‑risk appetite in the digital‑asset space contrasts sharply with the optimism that Cramer is showing for a biotech stock, suggesting that investors are looking for new avenues to diversify their risk.
For retail crypto investors, the takeaway is clear: while digital assets can offer rapid gains, they also carry heightened volatility. Adding a high‑growth biotech exposure like Moderna could provide a counterbalance, especially in a market that is still grappling with uncertainty. As the crypto market remains in a state of extreme fear, a well‑rounded portfolio might benefit from a mix of assets that can perform under different economic conditions.
What to watch next? Moderna’s upcoming earnings report, any new vaccine approvals, and regulatory developments will be key indicators of the company’s trajectory. Meanwhile, keep an eye on broader market moves—such as the latest Ripple announcement, Solana’s governance upgrade, and the Vanguard vs. State Street ETF showdown—since these events can shift investor sentiment across both traditional and digital asset classes.